ProKidney Corp. (PROK) - Total Liabilities
Based on the latest financial reports, ProKidney Corp. (PROK) has total liabilities worth $34.78 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore PROK shareholders equity momentum to track the company's year-over-year net asset growth rate.
ProKidney Corp. - Total Liabilities Trend (2019–2025)
This chart illustrates how ProKidney Corp.'s total liabilities have evolved over time, based on quarterly financial data.
ProKidney Corp. Competitors by Total Liabilities
The table below lists competitors of ProKidney Corp. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SOHO China Limited
F:45S
|
Germany | €30.88 Billion |
|
Indoco Remedies Limited
NSE:INDOCO
|
India | Rs16.61 Billion |
|
Yatsen Holding
NYSE:YSG
|
USA | $809.74 Million |
|
HMH Holding Inc. Class A Common Stock
NASDAQ:HMH
|
USA | $683.00 Million |
|
MacroGenics Inc
NASDAQ:MGNX
|
USA | $201.25 Million |
|
Lealea Enterprise Co Ltd
TW:1444
|
Taiwan | NT$9.08 Billion |
|
Cantor Equity Partners I, Inc. Class A Ordinary Shares
NASDAQ:CEPO
|
USA | $20.04 Million |
|
TFE Co. Ltd.
KQ:425420
|
Korea | ₩50.42 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down ProKidney Corp.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PROK company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ProKidney Corp.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ProKidney Corp. (2019–2025)
The table below shows the annual total liabilities of ProKidney Corp. from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $34.78 Million | -11.80% |
| 2024-12-31 | $39.44 Million | +34.98% |
| 2023-12-31 | $29.22 Million | +123.76% |
| 2022-12-31 | $13.06 Million | -2.42% |
| 2021-12-31 | $13.38 Million | +95.74% |
| 2020-12-31 | $6.84 Million | +83.57% |
| 2019-12-31 | $3.72 Million | -- |
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the devel… Read more